Sirnaomics is a clinical-stage RNA therapeutics biopharmaceutical company that is discovering and developing innovative drugs for indications with significant unmet medical needs in areas such as cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics. We are based in both the U.S. and China, having been founded in 2007 in Gaithersburg, Maryland.

Sirnaomics’ proprietary delivery platforms for RNA-based therapeutics are the foundation of our product pipeline. Our polypeptide nanoparticle delivery platform (PNP) is primarily used to administer mRNA vaccines and therapeutics. Our GalNAc delivery platform provides systemic administration for liver-targeting RNAi therapeutics.